Ultragenyx Pharmaceutical Inc at Jefferies London Healthcare Conference Transcript
Great pleasure that I'd like to welcome our guests today, Emil Kakkis, the President and CEO of Ultragenyx. Thanks so much for joining us, Emil. This is going to be a fireside chat format.
Questions & Answers
Maybe to start off for those who are new to the story, if you can provide a 1-minute intro to Ultragenyx.
Sure. I have to do that. Happy to be here in London again. Christmas already beginning. So Ultragenyx founded in 2010, we've been in business 13 years. We're a commercial company focused on rare diseases. We have 4 approved products generating $420 million, $450 million revenue this year. And we have 5 late-stage programs, Phase III programs and Phase II programs that are in a variety of indications. We've recently put out data at our Analyst Day on the 3 larger
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
